184 related articles for article (PubMed ID: 18243687)
41. BRCA2 is needed for both repair and cell cycle arrest in mammalian cells exposed to S23906, an anticancer monofunctional DNA binder.
Rocca CJ; Soares DG; Bouzid H; Henriques JA; Larsen AK; Escargueil AE
Cell Cycle; 2015; 14(13):2080-90. PubMed ID: 25945522
[TBL] [Abstract][Full Text] [Related]
42. Low cytotoxicity of ecteinascidin 743 in yeast lacking the major endonucleolytic enzymes of base and nucleotide excision repair pathways.
Soares DG; Poletto NP; Bonatto D; Salvador M; Schwartsmann G; Henriques JA
Biochem Pharmacol; 2005 Jul; 70(1):59-69. PubMed ID: 15913564
[TBL] [Abstract][Full Text] [Related]
43. Sensitivity of CHO mutant cell lines with specific defects in nucleotide excision repair to different anti-cancer agents.
Damia G; Imperatori L; Stefanini M; D'Incalci M
Int J Cancer; 1996 Jun; 66(6):779-83. PubMed ID: 8647649
[TBL] [Abstract][Full Text] [Related]
44. Anti-cancer effect and gene modulation of ET-743 in human biliary tract carcinoma preclinical models.
Peraldo-Neia C; Cavalloni G; Soster M; Gammaitoni L; Marchiò S; Sassi F; Trusolino L; Bertotti A; Medico E; Capussotti L; Aglietta M; Leone F
BMC Cancer; 2014 Dec; 14():918. PubMed ID: 25479910
[TBL] [Abstract][Full Text] [Related]
45. Investigations on the role of base excision repair and non-homologous end-joining pathways in sodium selenite-induced toxicity and mutagenicity in Saccharomyces cerevisiae.
Mániková D; Vlasáková D; Loduhová J; Letavayová L; Vigasová D; Krascsenitsová E; Vlcková V; Brozmanová J; Chovanec M
Mutagenesis; 2010 Mar; 25(2):155-62. PubMed ID: 19955329
[TBL] [Abstract][Full Text] [Related]
46. DNA repair and chromosomal alterations.
Natarajan AT; Palitti F
Mutat Res; 2008 Nov; 657(1):3-7. PubMed ID: 18801460
[TBL] [Abstract][Full Text] [Related]
47. Trabectedin (ET-743): evaluation of its use in advanced soft-tissue sarcoma.
Schöffski P; Wolter P; Clement P; Sciot R; De Wever I; Wozniak A; Stefan C; Dumez H
Future Oncol; 2007 Aug; 3(4):381-92. PubMed ID: 17661712
[TBL] [Abstract][Full Text] [Related]
48. Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedin.
Colmegna B; Uboldi S; Frapolli R; Licandro SA; Panini N; Galmarini CM; Badri N; Spanswick VJ; Bingham JP; Kiakos K; Erba E; Hartley JA; D'Incalci M
Br J Cancer; 2015 Dec; 113(12):1687-93. PubMed ID: 26633559
[TBL] [Abstract][Full Text] [Related]
49. The complexity of double-strand break ends is a factor in the repair pathway choice.
Mladenov E; Kalev P; Anachkova B
Radiat Res; 2009 Apr; 171(4):397-404. PubMed ID: 19397440
[TBL] [Abstract][Full Text] [Related]
50. Trabectedin as a chemotherapy option for patients with BRCA deficiency.
Monk BJ; Lorusso D; Italiano A; Kaye SB; Aracil M; Tanović A; D'Incalci M
Cancer Treat Rev; 2016 Nov; 50():175-182. PubMed ID: 27710871
[TBL] [Abstract][Full Text] [Related]
51. A review of trabectedin (ET-743): a unique mechanism of action.
D'Incalci M; Galmarini CM
Mol Cancer Ther; 2010 Aug; 9(8):2157-63. PubMed ID: 20647340
[TBL] [Abstract][Full Text] [Related]
52. Preclinical and clinical results with the natural marine product ET-743.
D'Incalci M; Jimeno J
Expert Opin Investig Drugs; 2003 Nov; 12(11):1843-53. PubMed ID: 14585059
[TBL] [Abstract][Full Text] [Related]
53. An inverse switch in DNA base excision and strand break repair contributes to melphalan resistance in multiple myeloma cells.
Sousa MM; Zub KA; Aas PA; Hanssen-Bauer A; Demirovic A; Sarno A; Tian E; Liabakk NB; Slupphaug G
PLoS One; 2013; 8(2):e55493. PubMed ID: 23405159
[TBL] [Abstract][Full Text] [Related]
54. Trabectedin mechanism of action: what's new?
D'Incalci M
Future Oncol; 2013 Dec; 9(12 Suppl):5-10. PubMed ID: 24195524
[TBL] [Abstract][Full Text] [Related]
55. Single-strand annealing, conservative homologous recombination, nonhomologous DNA end joining, and the cell cycle-dependent repair of DNA double-strand breaks induced by sparsely or densely ionizing radiation.
Frankenberg-Schwager M; Gebauer A; Koppe C; Wolf H; Pralle E; Frankenberg D
Radiat Res; 2009 Mar; 171(3):265-73. PubMed ID: 19267553
[TBL] [Abstract][Full Text] [Related]
56. Enhanced G2/M Arrest, Caspase Related Apoptosis and Reduced E-Cadherin Dependent Intercellular Adhesion by Trabectedin in Prostate Cancer Stem Cells.
Acikgoz E; Guven U; Duzagac F; Uslu R; Kara M; Soner BC; Oktem G
PLoS One; 2015; 10(10):e0141090. PubMed ID: 26485709
[TBL] [Abstract][Full Text] [Related]
57. Processing of anthracycline-DNA adducts via DNA replication and interstrand crosslink repair pathways.
Bilardi RA; Kimura KI; Phillips DR; Cutts SM
Biochem Pharmacol; 2012 May; 83(9):1241-50. PubMed ID: 22326903
[TBL] [Abstract][Full Text] [Related]
58. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair.
Takebayashi Y; Pourquier P; Zimonjic DB; Nakayama K; Emmert S; Ueda T; Urasaki Y; Kanzaki A; Akiyama SI; Popescu N; Kraemer KH; Pommier Y
Nat Med; 2001 Aug; 7(8):961-6. PubMed ID: 11479630
[TBL] [Abstract][Full Text] [Related]
59. Regulation of DNA repair in the absence of classical non-homologous end joining.
Kang YJ; Yan CT
DNA Repair (Amst); 2018 Aug; 68():34-40. PubMed ID: 29929045
[TBL] [Abstract][Full Text] [Related]
60. The impairment of the High Mobility Group A (HMGA) protein function contributes to the anticancer activity of trabectedin.
D'Angelo D; Borbone E; Palmieri D; Uboldi S; Esposito F; Frapolli R; Pacelli R; D'Incalci M; Fusco A
Eur J Cancer; 2013 Mar; 49(5):1142-51. PubMed ID: 23149213
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
